East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL)

Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/512632

Title:	East Asian subgroup analysis of a randomized, double-blind, phase 3 study of docetaxel and ramucirumab versus docetaxel and placebo in the treatment of stage IV non-small cell lung cancer following disease progression after one prior platinum-based therapy (REVEL)
Authors:	Park K. Kim J.-H. Cho E.K. Kang J.-H. JIN-YUAN SHIH Zimmermann A.H. Lee P. Alexandris E. Puri T. Orlando M.
Issue Date:	2016
Publisher:	Korean Cancer Association
Journal Volume:	48
Journal Issue:	4
Start page/Pages:	1177-1186
Source:	Cancer Research and Treatment
URI:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84996614772&doi=10.4143%2fcrt.2015.401&partnerID=40&md5=ea2a6ab7c054870f7c004fa055840947 https://scholars.lib.ntu.edu.tw/handle/123456789/512632
ISSN:	1598-2998
DOI:	10.4143/crt.2015.401
Appears in Collections:	醫學系

Show full item record

checked on Aug 28, 2020

checked on Jan 9, 2021

Check

DSpace CRIS